探索与relugolix和degarelix相关的心脏不良事件:基于FAERS数据库的多中心药监测研究
Meina Lv1, Jianhui Chen2, Bin Zheng1
1Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, China.
Expert opinion on drug safety
|April 3, 2025
概括
雷卢戈力克斯和脱力克斯是释放性腺激素的抗体,它们具有不同的心脏安全性. 雷卢戈利克斯与心电图异常和心有关,而德加利克斯与心力衰竭和心肌梗塞有关.
科学领域:
- 药物监督 药物监督 药物监督
- 心血管安全心血管安全
- 内分泌学 在内分泌学.
背景情况:
- 雷卢戈力克斯和脱力克斯是淋巴激素释放激素 (GnRH) 的对手.
- 对这些GnRH抗剂的真实心脏安全数据仍然有限.
- 这项研究调查了relugolix,degarelix和心脏不良事件之间的关联.
研究的目的:
- 探索relugolix和degarelix与心脏不良事件 (AE) 的潜在关联.
- 为了比较Relugolix和Degarelix的心脏安全概况.
主要方法:
- 利用FAERS数据库进行不良事件报告.
- 选择的报告,其中relugolix或degarelix是第一个可疑药物.
- 使用报告几率比率 (ROR) 和实证贝叶斯几何平均值 (EBGM) 的不成比例分析.
主要成果:
- 雷卢戈利克斯与心电图/心率异常和心有关.
- 德加莱克斯与心力衰竭,心肌梗塞和心律失常有关.
- 心脏AE主要影响老年患者 (>65岁).
结论:
- 雷卢戈力克斯和脱力克斯表现出不同的心脏不良事件概况.
- 临床医生应该意识到这些区别,并考虑加强对接受GNRH抗剂的患者的心电图监测.
相关概念视频
Pharmacovigilance
755
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
755
Internal Receptors
68.9K
Many cellular signals are hydrophilic and therefore cannot pass through the plasma membrane. However, small or hydrophobic signaling molecules can cross the hydrophobic core of the plasma membrane and bind to internal, or intracellular, receptors that reside within the cell. Many mammalian steroid hormones use this mechanism of cell signaling, as does nitric oxide (NO) gas.
68.9K
Drug Regulation
1.3K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.3K
Cardiovascular Drugs: Classification based on Therapeutic Indications
1.9K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
1.9K
Heart Failure Drugs: β-Blockers
284
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
284
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
409
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
409


